phenobarbital has been researched along with Abstinence Syndrome, Neonatal in 62 studies
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eight sites enrolled 116 full-term newborn infants with neonatal abstinence syndrome born to mothers maintained on methadone or buprenorphine into a randomized trial of morphine vs methadone." | 9.34 | Neurodevelopmental Outcomes of Neonates Randomized to Morphine or Methadone for Treatment of Neonatal Abstinence Syndrome. ( Bogen, DL; Czynski, AJ; Dansereau, LM; Davis, JM; Engelhardt, B; Hudak, ML; Lester, BM; Marro, P; Oliveira, EL; Shenberger, J; Wachman, EM, 2020) |
| "In this single-site, double-blind, double-dummy clinical trial, we randomly assigned 63 term infants (≥37 weeks of gestation) who had been exposed to opioids in utero and who had signs of the neonatal abstinence syndrome to receive either sublingual buprenorphine or oral morphine." | 9.24 | Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. ( Abatemarco, D; Adeniyi-Jones, SC; Chervoneva, I; Ehrlich, ME; Greenspan, JS; Kaltenbach, K; Kraft, WK, 2017) |
| "To compare the efficacy of clonidine versus phenobarbital in reducing morphine sulfate treatment days for neonatal abstinence syndrome (NAS)." | 9.17 | Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. ( Chamberlain, S; Kopcza, K; Shah, B; Singh, R; Surran, B; Visintainer, P, 2013) |
| "The aim of the study is to assess the correlation between maternal methadone dose and severity of neonatal abstinence syndrome (NAS) in infants that required pharmacological treatment for NAS." | 8.12 | Is Maternal Methadone Dose Associated with the Severity of Neonatal Abstinence Syndrome? ( Adeniyi-Jones, S; Aghai, ZH; Boelig, RC; Carola, D; Greenspan, JS; Kraft, WK; Lafferty, M; Smith, J, 2022) |
| "This pilot study evaluated the relationship between maternal and neonatal R- and S-methadone and R- and S-2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) exposure and the severity of neonatal abstinence syndrome (NAS)." | 8.02 | Stereoselective Analysis of Methadone and EDDP in Laboring Women and Neonates in Plasma and Dried Blood Spots and Association with Neonatal Abstinence Syndrome. ( Evrard, CA; Haas, DM; Haneline, LS; Jones, DR; Masters, AR; Metzger, IF; Quinney, SK; Thomas, AE, 2021) |
| "To compare clonidine versus phenobarbital as adjunctive therapy in infants who failed monotherapy with morphine for neonatal abstinence syndrome (NAS)." | 7.96 | Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. ( Brusseau, C; Burnette, T; Heidel, RE, 2020) |
| "Neonatal abstinence syndrome (NAS) due to prenatally exposure to citalopram can develop during the first days of life even with low dose of drug exposure." | 7.85 | Neonatal abstinence syndrome due to prenatally citalopram exposure: A case report. ( Bas, AY; Celik, IH; Demirel, N; Erol, S; Ozcan, B, 2017) |
| "The development, characterization and stability evaluation of methadone (MI, MII, MIII) and phenobarbital (PI, PII) can be used for the treatment of neonatal abstinence syndrome (NAS)." | 7.83 | Design of pediatric oral formulations with a low proportion of methadone or phenobarbital for the treatment of neonatal abstinence syndrome. ( Calpena, AC; Clares, B; Mallandrich, M; Provenza, N; Pueyo, B, 2016) |
| "When tramadol is used during pregnancy, there is a serious risk for neonatal abstinence syndrome." | 7.79 | [Neonatal abstinence syndrome after maternal use of tramadol]. ( de Wit, D; Koomen-Botman, I, 2013) |
| " All of these patients were born to mothers who had received methadone substitution for drug addiction during the course of pregnancy." | 7.76 | Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate. ( Bastanier, C; Beske, F; Esmaeili, A; Keinhorst, AK; Schlösser, R; Schuster, T, 2010) |
| "This was a retrospective chart review of 68 neonates and their mothers who received methadone therapy during pregnancy." | 7.75 | High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. ( Cordero, L; Gardner, DK; Lim, S; Prasad, MR; Samuels, P, 2009) |
| "Three suitable compounds (morphine, chlorpromazine, and phenobarbital) to treat neonatal abstinence syndrome were compared in a prospective multicenter, double-blind trial." | 5.34 | Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. ( Bucher, HU; Duò, A; Held, L; Rudin, C; Zimmermann, U, 2020) |
| "Eight sites enrolled 116 full-term newborn infants with neonatal abstinence syndrome born to mothers maintained on methadone or buprenorphine into a randomized trial of morphine vs methadone." | 5.34 | Neurodevelopmental Outcomes of Neonates Randomized to Morphine or Methadone for Treatment of Neonatal Abstinence Syndrome. ( Bogen, DL; Czynski, AJ; Dansereau, LM; Davis, JM; Engelhardt, B; Hudak, ML; Lester, BM; Marro, P; Oliveira, EL; Shenberger, J; Wachman, EM, 2020) |
| "In this single-site, double-blind, double-dummy clinical trial, we randomly assigned 63 term infants (≥37 weeks of gestation) who had been exposed to opioids in utero and who had signs of the neonatal abstinence syndrome to receive either sublingual buprenorphine or oral morphine." | 5.24 | Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. ( Abatemarco, D; Adeniyi-Jones, SC; Chervoneva, I; Ehrlich, ME; Greenspan, JS; Kaltenbach, K; Kraft, WK, 2017) |
| "To compare the efficacy of clonidine versus phenobarbital in reducing morphine sulfate treatment days for neonatal abstinence syndrome (NAS)." | 5.17 | Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. ( Chamberlain, S; Kopcza, K; Shah, B; Singh, R; Surran, B; Visintainer, P, 2013) |
| " The mothers received methadone (n=22), slow-release oral morphine (n=17) or buprenorphine (n=14) throughout pregnancy." | 5.12 | Management of neonatal abstinence syndrome in neonates born to opioid maintained women. ( Baewert, A; Ebner, N; Fischer, G; Jagsch, R; Peternell, A; Rohrmeister, K; Thau, K; Winklbaur, B, 2007) |
| "The aim of the study is to assess the correlation between maternal methadone dose and severity of neonatal abstinence syndrome (NAS) in infants that required pharmacological treatment for NAS." | 4.12 | Is Maternal Methadone Dose Associated with the Severity of Neonatal Abstinence Syndrome? ( Adeniyi-Jones, S; Aghai, ZH; Boelig, RC; Carola, D; Greenspan, JS; Kraft, WK; Lafferty, M; Smith, J, 2022) |
| "This pilot study evaluated the relationship between maternal and neonatal R- and S-methadone and R- and S-2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) exposure and the severity of neonatal abstinence syndrome (NAS)." | 4.02 | Stereoselective Analysis of Methadone and EDDP in Laboring Women and Neonates in Plasma and Dried Blood Spots and Association with Neonatal Abstinence Syndrome. ( Evrard, CA; Haas, DM; Haneline, LS; Jones, DR; Masters, AR; Metzger, IF; Quinney, SK; Thomas, AE, 2021) |
| "To compare clonidine versus phenobarbital as adjunctive therapy in infants who failed monotherapy with morphine for neonatal abstinence syndrome (NAS)." | 3.96 | Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. ( Brusseau, C; Burnette, T; Heidel, RE, 2020) |
| "Neonatal abstinence syndrome (NAS) due to prenatally exposure to citalopram can develop during the first days of life even with low dose of drug exposure." | 3.85 | Neonatal abstinence syndrome due to prenatally citalopram exposure: A case report. ( Bas, AY; Celik, IH; Demirel, N; Erol, S; Ozcan, B, 2017) |
| "The development, characterization and stability evaluation of methadone (MI, MII, MIII) and phenobarbital (PI, PII) can be used for the treatment of neonatal abstinence syndrome (NAS)." | 3.83 | Design of pediatric oral formulations with a low proportion of methadone or phenobarbital for the treatment of neonatal abstinence syndrome. ( Calpena, AC; Clares, B; Mallandrich, M; Provenza, N; Pueyo, B, 2016) |
| "When tramadol is used during pregnancy, there is a serious risk for neonatal abstinence syndrome." | 3.79 | [Neonatal abstinence syndrome after maternal use of tramadol]. ( de Wit, D; Koomen-Botman, I, 2013) |
| " All of these patients were born to mothers who had received methadone substitution for drug addiction during the course of pregnancy." | 3.76 | Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate. ( Bastanier, C; Beske, F; Esmaeili, A; Keinhorst, AK; Schlösser, R; Schuster, T, 2010) |
| "This was a retrospective chart review of 68 neonates and their mothers who received methadone therapy during pregnancy." | 3.75 | High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. ( Cordero, L; Gardner, DK; Lim, S; Prasad, MR; Samuels, P, 2009) |
| "Ondansetron treatment reduced the severity of NOWS symptoms; and there was an indication that it could reduce the length of stay." | 3.30 | Ondansetron to reduce neonatal opioid withdrawal severity a randomized clinical trial. ( Adeniyi-Jones, S; Argani, C; Cohane, C; Drover, D; Govindaswami, B; Jansson, LM; Jegatheesan, P; Khan, S; Kraft, WK; Peltz, G; Shafer, S; Wang, M; Wu, M, 2023) |
| " Mean cumulative dosage of ch was 643." | 2.78 | Treatment of neonatal abstinence syndrome in preterm and term infants. ( Dabek, MT; Englert, S; Poeschl, J; Ruef, P, 2013) |
| "When opioid misuse rises in the United States, pregnant women and their neonates are affected." | 2.61 | Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome. ( Jones, HE; Kraft, WK, 2019) |
| "Phenobarbital levels were higher in symptomatic infants than asymptomatic infants, although the difference was not statistically significant." | 1.37 | Infants born to mothers under phenobarbital treatment: correlation between serum levels and clinical features of neonates. ( Antichi, E; Cardiello, V; Carducci, C; Catenazzi, P; D'Antuono, A; Piras, A; Pozzoli, G; Romagnoli, C; Scorrano, A; Zuppa, AA, 2011) |
| "To determine the monitoring and treatment of neonatal abstinence syndrome (NAS) in neonatal intensive care units (NICUs) following opiate or polydrug exposure in utero." | 1.33 | Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. ( Donn, SM; Sarkar, S, 2006) |
| "Symptoms of the neonatal withdrawal syndrome are excitation of the central nervous system, the gastrointestinal tract and the respiratory tract." | 1.33 | [A multidisciplinary approach is necessary in the neonatal withdrawal syndrome]. ( Clement-de Boers, A; de Vries, MC; Leeuwenburgh-Pronk, WG, 2006) |
| "Maternal drug addiction has increased in an alarming way over the last ten years." | 1.28 | [Newborn infant of drug-addicted mother: maternal, perinatal, neonatal aspects, and neonatal abstinence syndrome]. ( Arcas Cruz, R; Comas Mastmitja, L; Cruz Hernández, M; Figueras Aloy, J; Jiménez González, R; Vilanova Juanola, JM, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.84) | 18.7374 |
| 1990's | 7 (11.29) | 18.2507 |
| 2000's | 11 (17.74) | 29.6817 |
| 2010's | 29 (46.77) | 24.3611 |
| 2020's | 12 (19.35) | 2.80 |
| Authors | Studies |
|---|---|
| Friedman, D | 1 |
| Zubair, N | 1 |
| Favara, MT | 1 |
| Lafferty, M | 2 |
| Carola, D | 2 |
| Adeniyi-Jones, S | 3 |
| Solarin, K | 1 |
| Aghai, ZH | 2 |
| Peltz, G | 1 |
| Jansson, LM | 1 |
| Cohane, C | 1 |
| Drover, D | 1 |
| Shafer, S | 1 |
| Wang, M | 1 |
| Wu, M | 1 |
| Govindaswami, B | 1 |
| Jegatheesan, P | 1 |
| Argani, C | 1 |
| Khan, S | 1 |
| Kraft, WK | 5 |
| Leferink, TM | 1 |
| van der Meer-Kappelle, LH | 1 |
| Feberwee, T | 1 |
| MacMillan, KDL | 1 |
| Zimmermann, U | 1 |
| Rudin, C | 1 |
| Duò, A | 1 |
| Held, L | 1 |
| Bucher, HU | 1 |
| Clemans-Cope, L | 1 |
| Holla, N | 1 |
| Lee, HC | 1 |
| Cong, AS | 1 |
| Castro, R | 1 |
| Chyi, L | 1 |
| Huang, A | 1 |
| Taylor, KJ | 1 |
| Kenney, GM | 1 |
| Czynski, AJ | 2 |
| Davis, JM | 1 |
| Dansereau, LM | 1 |
| Engelhardt, B | 1 |
| Marro, P | 1 |
| Bogen, DL | 1 |
| Hudak, ML | 1 |
| Shenberger, J | 1 |
| Wachman, EM | 1 |
| Oliveira, EL | 1 |
| Lester, BM | 2 |
| Metzger, IF | 1 |
| Thomas, AE | 1 |
| Evrard, CA | 1 |
| Jones, DR | 1 |
| Masters, AR | 1 |
| Haas, DM | 1 |
| Haneline, LS | 1 |
| Quinney, SK | 1 |
| Brusseau, C | 1 |
| Burnette, T | 1 |
| Heidel, RE | 1 |
| Smith, J | 1 |
| Boelig, RC | 1 |
| Greenspan, JS | 3 |
| Merhar, SL | 1 |
| Ounpraseuth, S | 1 |
| Devlin, LA | 1 |
| Poindexter, BB | 1 |
| Young, LW | 1 |
| Berkey, SD | 1 |
| Crowley, M | 2 |
| Kiefer, AS | 1 |
| Whalen, BL | 1 |
| Das, A | 1 |
| Fuller, JF | 1 |
| Higgins, RD | 1 |
| Thombre, V | 1 |
| Smith, PB | 1 |
| Newman, S | 1 |
| Sánchez, PJ | 1 |
| Smith, MC | 1 |
| Simon, AE | 1 |
| Zankl, A | 2 |
| Martin, J | 2 |
| Davey, JG | 2 |
| Osborn, DA | 7 |
| Adeniyi-Jones, SC | 1 |
| Chervoneva, I | 1 |
| Abatemarco, D | 1 |
| Kaltenbach, K | 2 |
| Ehrlich, ME | 2 |
| Erol, S | 1 |
| Ozcan, B | 1 |
| Celik, IH | 1 |
| Bas, AY | 1 |
| Demirel, N | 1 |
| Maalouf, FI | 1 |
| Cooper, WO | 1 |
| Slaughter, JC | 1 |
| Dudley, J | 1 |
| Patrick, SW | 2 |
| Jones, HE | 1 |
| de Wit, D | 1 |
| Koomen-Botman, I | 1 |
| Dabek, MT | 1 |
| Poeschl, J | 1 |
| Englert, S | 1 |
| Ruef, P | 1 |
| Surran, B | 1 |
| Visintainer, P | 1 |
| Chamberlain, S | 1 |
| Kopcza, K | 1 |
| Shah, B | 1 |
| Singh, R | 2 |
| Smirk, CL | 1 |
| Bowman, E | 1 |
| Doyle, LW | 1 |
| Kamlin, O | 1 |
| Kaplan, HC | 1 |
| Passarella, M | 1 |
| Davis, MM | 1 |
| Lorch, SA | 1 |
| Coyle, MG | 3 |
| Visintainer, PF | 1 |
| Hall, ES | 1 |
| Wexelblatt, SL | 1 |
| Grow, JL | 1 |
| Jasin, LR | 1 |
| Klebanoff, MA | 1 |
| McClead, RE | 1 |
| Meinzen-Derr, J | 1 |
| Mohan, VK | 1 |
| Stein, H | 1 |
| Walsh, MC | 1 |
| Ruwanpathirana, R | 1 |
| Abdel-Latif, ME | 2 |
| Burns, L | 1 |
| Chen, J | 1 |
| Craig, F | 2 |
| Lui, K | 2 |
| Oei, JL | 1 |
| Nayeri, F | 1 |
| Sheikh, M | 1 |
| Kalani, M | 1 |
| Niknafs, P | 1 |
| Shariat, M | 1 |
| Dalili, H | 1 |
| Dehpour, AR | 1 |
| Provenza, N | 1 |
| Calpena, AC | 1 |
| Mallandrich, M | 1 |
| Pueyo, B | 1 |
| Clares, B | 1 |
| Raith, W | 1 |
| Schmölzer, GM | 1 |
| Resch, B | 1 |
| Reiterer, F | 1 |
| Avian, A | 1 |
| Koestenberger, M | 1 |
| Urlesberger, B | 1 |
| Holmes, AV | 1 |
| Atwood, EC | 1 |
| Whalen, B | 1 |
| Beliveau, J | 1 |
| Jarvis, JD | 1 |
| Matulis, JC | 1 |
| Ralston, SL | 1 |
| McPherson, C | 1 |
| Mücke, S | 1 |
| Nagel, M | 1 |
| Siedentopf, J | 1 |
| Bührer, C | 1 |
| Hüseman, D | 1 |
| Winklbaur, B | 2 |
| Kopf, N | 1 |
| Ebner, N | 2 |
| Jung, E | 1 |
| Thau, K | 2 |
| Fischer, G | 2 |
| Lim, S | 1 |
| Prasad, MR | 1 |
| Samuels, P | 1 |
| Gardner, DK | 1 |
| Cordero, L | 1 |
| Esmaeili, A | 1 |
| Keinhorst, AK | 1 |
| Schuster, T | 1 |
| Beske, F | 1 |
| Schlösser, R | 1 |
| Bastanier, C | 1 |
| Hartenstein, S | 1 |
| Proquitté, H | 1 |
| Bauer, S | 1 |
| Bamberg, C | 1 |
| Roehr, CC | 1 |
| Dysart, K | 1 |
| Gibson, E | 1 |
| Jeffery, HE | 5 |
| Cole, MJ | 4 |
| Zuppa, AA | 1 |
| Carducci, C | 1 |
| Scorrano, A | 1 |
| Antichi, E | 1 |
| Catenazzi, P | 1 |
| Piras, A | 1 |
| Pozzoli, G | 1 |
| Cardiello, V | 1 |
| D'Antuono, A | 1 |
| Romagnoli, C | 1 |
| Bio, LL | 1 |
| Siu, A | 1 |
| Poon, CY | 1 |
| Kieviet, N | 1 |
| Dolman, K | 1 |
| Wennink, H | 1 |
| Heres, M | 1 |
| Honig, A | 1 |
| Oei, J | 1 |
| Jackson, L | 1 |
| Ting, A | 1 |
| McKay, S | 1 |
| Galea, P | 1 |
| Skeoch, C | 1 |
| Ferguson, A | 2 |
| Lagasse, L | 2 |
| Liu, J | 1 |
| Lester, B | 2 |
| Cole, M | 1 |
| Sarkar, S | 1 |
| Donn, SM | 1 |
| Leeuwenburgh-Pronk, WG | 1 |
| de Vries, MC | 1 |
| Clement-de Boers, A | 1 |
| Rohrmeister, K | 1 |
| Baewert, A | 1 |
| Jagsch, R | 1 |
| Peternell, A | 1 |
| Lam, SK | 1 |
| To, WK | 1 |
| Kandall, SR | 1 |
| Tenenbein, M | 1 |
| Casiro, OG | 1 |
| Seshia, MM | 1 |
| Debooy, VD | 1 |
| Morrison, CL | 1 |
| Siney, C | 1 |
| Theis, JG | 1 |
| Selby, P | 1 |
| Ikizler, Y | 1 |
| Koren, G | 1 |
| Oh, W | 1 |
| Kattner, E | 1 |
| Arcas Cruz, R | 1 |
| Figueras Aloy, J | 1 |
| Vilanova Juanola, JM | 1 |
| Comas Mastmitja, L | 1 |
| Jiménez González, R | 1 |
| Cruz Hernández, M | 1 |
| Torrence, CR | 1 |
| Horns, KM | 1 |
| Torriolo, MG | 1 |
| Steffanini, MC | 1 |
| Mariotti, P | 1 |
| Calzolari, S | 1 |
| Fundaro, C | 1 |
| Tempesta, E | 1 |
| Thomas, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| AIM 2- Prevention of Neonatal Abstinence Syndrome[NCT01965704] | Phase 2 | 196 participants (Actual) | Interventional | 2014-09-09 | Completed | ||
| Pharmacological Treatment of Narcotic Neonatal Withdrawal[NCT02810782] | Phase 3 | 120 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Improving Outcomes in Neonatal Abstinence Syndrome[NCT01958476] | Phase 3 | 117 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome[NCT02851303] | Phase 4 | 61 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Pharmacological Treatment of Neonatal Abstinence Syndrome: Opiate Versus Non-Opiate[NCT01734551] | Phase 4 | 31 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy[NCT03092011] | Phase 4 | 90 participants (Anticipated) | Interventional | 2018-02-21 | Recruiting | ||
| Treatment of Neonatal Abstinence Syndrome: Evaluation of Efficacy of Phenobarbital in Combination With Either Methadone or Diluted Deodorized Tincture of Opium as Stabilizing and Tapering Regiments[NCT01723722] | Phase 4 | 40 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Randomized, Active-Control, Double-Blind, Double-Dummy Clinical Trial Comparing Sublingual Buprenorphine And Morphine Solution For The Treatment Of Neonatal Opioid Abstinence Syndrome[NCT01452789] | Phase 3 | 63 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Randomized Comparison of Sublingual Buprenorphine to Morphine Sulfate in the Treatment of Neonatal Abstinence Syndrome (NAS)[NCT01708707] | Phase 2 | 29 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Comparison of Clonidine Versus Phenobarbital as an Adjunct Therapy for Neonatal Abstinence Syndrome[NCT01175668] | 68 participants (Actual) | Interventional | 2010-07-31 | Terminated (stopped due to Based on the planned interim analysis results at 50% recruitment, after IRB reviewed the results, further enrollment was stopped.) | |||
| Auricular Acupressure as an Adjunct Treatment for Opioid Tapering in a Pediatric Cardiac Intensive Care Unit: A Pilot Feasibility Study[NCT05025384] | 40 participants (Actual) | Interventional | 2021-10-25 | Completed | |||
| Buprenorphine for the Treatment of Neonatal Abstinence Syndrome[NCT00521248] | Phase 1 | 60 participants (Anticipated) | Interventional | 2004-04-30 | Completed | ||
| Prospective Randomized Blinded Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)[NCT04455802] | Phase 3 | 0 participants (Actual) | Interventional | 2020-10-01 | Withdrawn (stopped due to termination of funding) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of neonates requiring treatment with phenobarbital or clonidine. (NCT01965704)
Timeframe: 15 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Ondansetron - Neonates | 5 |
| Placebo - Neonates | 5 |
The incidence of neonatal abstinence syndrome (NAS) measured as the number of neonates who need for morphine treatment for the symptoms of neonatal opioid withdrawal syndrome (NOWS) while the neonates received study medication and for the 30 days after stopping the study medication. (NCT01965704)
Timeframe: 35 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Ondansetron - Neonates | 22 |
| Placebo - Neonates | 26 |
Median dose of morphine required by neonates within 15 days of delivery. (NCT01965704)
Timeframe: 15 days
| Intervention | mg (Median) |
|---|---|
| Ondansetron - Neonates | 9.3 |
| Placebo - Neonates | 11.1 |
Severity of NAS will be measured by neonates' length of hospital stay (birth to discharge). Length of stay was calculated with 1) no maximum length, and 2) maximum length of stay capped at 15 days. All participants were included in both analyses. (NCT01965704)
Timeframe: At Day 15 and up to 64 days
| Intervention | days (Mean) | |
|---|---|---|
| Mean hospital stay | Mean hospital stay with a 15-day maximum | |
| Ondansetron - Neonates | 15.5 | 9.3 |
| Placebo - Neonates | 17.4 | 11.2 |
Average head circumference growth outcome at 18 month follow-up visit. (NCT01958476)
Timeframe: 18 month follow-up visit
| Intervention | cm (Mean) |
|---|---|
| Methadone | 47.8 |
| Neonatal Morphine Solution | 48.2 |
Average length (cm) at 18 month follow-up visit. (NCT01958476)
Timeframe: 18 month follow-up visit
| Intervention | cm (Mean) |
|---|---|
| Methadone | 82.1 |
| Neonatal Morphine Solution | 81.7 |
Growth outcome weight (lbs) depicted as difference in averaged weights from birth to 18 month follow-up visit. Standard deviations were averaged between birth and 18 mo time points. (NCT01958476)
Timeframe: Birth to 18 month follow-up visit
| Intervention | lbs (Mean) |
|---|---|
| Methadone | 19.1 |
| Neonatal Morphine Solution | 18.7 |
Participants were monitored for the duration of their hospitalization, an expected mean of 22 days. (NCT01958476)
Timeframe: Participants will be monitored during their entire hospitalization, expected mean 22 days.
| Intervention | days (Mean) |
|---|---|
| Methadone | 21.8 |
| Neonatal Morphine Solution | 23.2 |
Participants were monitored for the duration of their hospitalization attributable to NAS only. (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, expected mean 22 days.
| Intervention | days (Mean) |
|---|---|
| Methadone | 18.9 |
| Neonatal Morphine Solution | 21.1 |
Total number of days infant treated with replacement opioids while admitted to the hospital. (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization.
| Intervention | days (Mean) |
|---|---|
| Methadone | 14.7 |
| Neonatal Morphine Solution | 16.6 |
"One Finnegan score ≥12, or two consecutive scores ≥8 affirms the requirement for pharmacological treatment or increasing treatment dosage. If the infant continued to have two consecutive Finnegan Scores ≥8 two times consecutively, or one ≥12, the dose was increased to the next level. (Level I: 0.3 mg/kg/day) (Level II: 0.5 mg/kg/day) (Level III: 0.7 mg/kg/day)~A higher Finnegan score indicates greater severity of NAS (min 0, max 50)." (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, an average of 22 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Methadone | 22 |
| Neonatal Morphine Solution | 28 |
Number of infants treated with a second medication following protocol, phenobarbital. If the Finnegan Score remained elevated (still scored ≥8 two times consecutively, or still scored once ≥12) despite increasing to a predetermined maximal opioid dose (methadone or morphine), phenobarbital was administered (20-mg/kg loading dose followed by 4-5 mg/kg daily). (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, an average of 22 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Methadone | 10 |
| Neonatal Morphine Solution | 17 |
The Bayley Scales of Infant and Toddler Development (BSID-III) assesses the development of infants and children (1-42 months) through a series of developmental play tasks, identifying children with developmental delay. Raw scores of completed items are summarized within three distinct scale scores (Cognitive Scale, Language Scale, Motor Scale). Scale scores are each converted to composite scores to determine the child's performance compared with scores of age-matched children of typical development (percentile rank). A higher composite score indicates more ideal developmental outcome (range 40-160). At 18 month follow-up visit, participants were assessed using the BSID-III for cognitive, language and motor scale composite score outcomes. (NCT01958476)
Timeframe: Assessment at 18 month follow-up visit
| Intervention | scores on a scale (Composite) (Mean) | ||
|---|---|---|---|
| Cognitive Composite | Language Composite | Motor Composite | |
| Methadone | 100.1 | 96.0 | 103.6 |
| Neonatal Morphine Solution | 98.1 | 94.2 | 99.1 |
Assessed through chart review of discharge summary documentation of method of infant feeding at time of discharge (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 5 |
| Methadone | 5 |
Number of days in hospital after birth (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | days (Mean) |
|---|---|
| Morphine | 17.9 |
| Methadone | 16.1 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | days (Mean) |
|---|---|
| Morphine | 14.7 |
| Methadone | 12.8 |
clonidine (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 1 |
| Methadone | 0 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 11 |
| Methadone | 6 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 0 |
| Methadone | 3 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | morphine equivalents mg (Mean) |
|---|---|
| Morphine | 9.86 |
| Methadone | 33.0 |
Total number days of treatment (NCT01734551)
Timeframe: 120 days
| Intervention | days (Median) |
|---|---|
| Morphine | 39 |
| Clonidine | 27 |
Scores obtained Bayley Scales of Infant and Toddler Development Third Edition in the developmental domains of motor, cognitive, and language. This tool for measures of motor, cognitive and language development is a series of standardized measurements and for each domain, the standardized scores have a mean of 100 and standard deviation of 15. Scores below 1 standard deviation (= or less than 84) is considered below normal. Scores above 1 standard deviation (over 115) represent higher than normal functioning in each domain The score for each domain (motor, cognitive, and language functioning) represents the full-scale score (NCT01734551)
Timeframe: 1 year of life
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Bayley III motor | Cognitive | Language total | Language Receptive | Language Expressive | |
| Clonidine | 95.8 | 93.3 | 95.8 | 95.0 | 99.2 |
| Morphine | 97.6 | 92.9 | 98.0 | 101.1 | 100.0 |
Mean of total Finnegan Scores obtained every 3 hours on days 2, 7, and 14 following start of treatment; A score is a number representing the total score or sum from 21 items or symptoms or manifestations of opiate withdrawal in newborn infants. The total score ranges from 0 to 43. Reference: 1. Finnegan LP, Connaughton JF, Jr., Kron RE, et al. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975;2(1-2):141-58. Although normal newborn may manifest mild symptoms that will give scores in the range of 0 to 7. A score of 8 consecutively obtained times 3 indicate that infant will benefit from treatment, in this study morphine or clonidine. A decrease in scores especially to less than 8 is suggestive of a good response to treatment. (NCT01734551)
Timeframe: 14 days
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Finnegan scores day 2 of treatment | Finnegan scores day 7 of treatment | Finnegan scores day 14 of treatment | |
| Clonidine | 8.5 | 5.7 | 6.7 |
| Morphine | 7.5 | 6.6 | 7.1 |
The summary scores from the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) give a measure of infant neurobehavior in the following areas (score range): habituation (1-9), regulation (2.20-7.50), attention (1.29 -8.4), Handling (0 - 1), quality of movement (1.20 - 6.20), Non-optimal reflexes (0-12), Asymmetric reflexes (0-7), arousal (2.43 - 6.67), hypertonicity (0- 8), hypotonicity (0 - 5.0), excitability (0-11), lethargy (0 - 11.0). and stress/abstinence (0. - 0.57). A higher score for each item means a higher level of the construct. For example, a higher score for hypertonicity means the infant is more hypertonic and higher score on hypotonicity means the infant is more hypotonic. No cut-off score published for normal or abnormal behavioral performance. Reference: Lester BM et al. Summary Statistics of Neonatal Intensive Care Unit Network Neurobehavioral Scale Scores From the Maternal Lifestyle Study: A Quasinormative Sample, in Pediatrics 2004; 113,668. (NCT01734551)
Timeframe: 5-10 days after treatment starts
| Intervention | scores on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Attention | Handling | Quality of movement | Regulation | Non-optimal reflexes | Asymmetric reflexes | Stress/abstinence | Arousal | Hypertonicity | Hypotonicity | Excitability | Lethargy | |
| Clonidine | 4.51 | 0.42 | 4.92 | 5.26 | 4.13 | 0.00 | 0.08 | 3.95 | 0.25 | 0.19 | 2.38 | 5.13 |
| Morphine | 5.06 | 0.36 | 4.77 | 5.2 | 3.73 | 0.20 | 0.07 | 3.91 | 0.40 | 0.13 | 2.6 | 3.6 |
Up to 12 months (NCT01723722)
Timeframe: Up to 12 months
| Intervention | days (Mean) |
|---|---|
| Deodorized Tincture Opium After Phenobarbital for Withdrawal | 19.1 |
| Methadone After Phenobarbital for Withdrawal | 17.7 |
This endpoint will compare length of stay in the hospital (in days) using sublingual buprenorphine or morphine solution. (NCT01452789)
Timeframe: Duration of hospital stay is an expected average of 5 weeks.
| Intervention | days (Median) |
|---|---|
| Sublingual Buprenorphine | 21 |
| Oral Morphine | 33 |
This endpoint will compare length of treatment (in days) using sublingual buprenorphine or oral morphine solution. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | days (Median) |
|---|---|
| Sublingual Buprenorphine | 15 |
| Oral Morphine | 28 |
Adverse events will be collected, graded by severity, and assessed for causality referent to study drug. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sublingual Buprenorphine | 7 |
| Oral Morphine | 8 |
This endpoint will compare requirement number of patients who require use of supplemental phenobarbital. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | participants (Number) |
|---|---|
| Sublingual Buprenorphine | 5 |
| Oral Morphine | 7 |
(NCT01175668)
Timeframe: subjects were followed for the duration of treatment, up to 3 months
| Intervention | days (Mean) |
|---|---|
| NMS/Clonidine | 18.2 |
| NMS/Phenobarbital | 13.6 |
(NCT01175668)
Timeframe: For the duration of treatment, upto 3 months
| Intervention | mg/kg (Mean) |
|---|---|
| NMS/Clonidine | 5.7 |
| NMS/Phenobarbital | 4.6 |
16 reviews available for phenobarbital and Abstinence Syndrome, Neonatal
| Article | Year |
|---|---|
Neonatal Abstinence Syndrome: Review of Epidemiology, Care Models, and Current Understanding of Outcomes.
Topics: Analgesics, Opioid; Breast Feeding; Buprenorphine; Female; Humans; Hypnotics and Sedatives; Infant, | 2019 |
Sedatives for opioid withdrawal in newborn infants.
Topics: Bias; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Narcoti | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome.
Topics: Analgesia, Obstetrical; Analgesics; Analgesics, Opioid; Breast Feeding; Buprenorphine; Buprenorphine | 2019 |
Pharmacotherapy for Neonatal Abstinence Syndrome: Choosing the Right Opioid or No Opioid at All.
Topics: Analgesics; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans; Hypnotics and Sedatives; In | 2016 |
Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates.
Topics: Buprenorphine; Diagnosis, Dual (Psychiatry); Female; GABA Modulators; Humans; Infant, Newborn; Menta | 2008 |
Sedatives for opiate withdrawal in newborn infants.
Topics: Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Narcotics; Ne | 2010 |
Opiate treatment for opiate withdrawal in newborn infants.
Topics: Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Morphine; Narcotics; Neonatal Abstinence | 2010 |
Update on the pharmacologic management of neonatal abstinence syndrome.
Topics: Benzodiazepines; Buprenorphine; Clonidine; Female; Humans; Hypnotics and Sedatives; Infant, Newborn; | 2011 |
[Withdrawal in newborns after exposure to psychotropic medications during pregnancy].
Topics: Anticonvulsants; Female; Humans; Infant, Newborn; Male; Neonatal Abstinence Syndrome; Phenobarbital; | 2012 |
Sedatives for opiate withdrawal in newborn infants.
Topics: Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Neonatal Abst | 2002 |
Sedatives for opiate withdrawal in newborn infants.
Topics: Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Neonatal Abst | 2005 |
Opiate treatment for opiate withdrawal in newborn infants.
Topics: Diazepam; Humans; Infant, Newborn; Narcotics; Neonatal Abstinence Syndrome; Opioid-Related Disorders | 2005 |
Treatment options for drug-exposed infants.
Topics: Female; GABA Modulators; Humans; Infant, Newborn; Naloxone; Narcotic Antagonists; Narcotics; Neonata | 1995 |
Current management of the neonatal abstinence syndrome: a critical analysis of the evidence.
Topics: Analgesics, Opioid; Anticonvulsants; Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; | 1997 |
[Findings in newborn infants following drug abuse or drug weaning in the mother].
Topics: Abnormalities, Drug-Induced; Adult; Female; Fetal Growth Retardation; Heroin Dependence; Humans; Inf | 1991 |
13 trials available for phenobarbital and Abstinence Syndrome, Neonatal
| Article | Year |
|---|---|
Ondansetron to reduce neonatal opioid withdrawal severity a randomized clinical trial.
Topics: Analgesics, Opioid; Humans; Infant, Newborn; Morphine; Neonatal Abstinence Syndrome; Ondansetron; Ph | 2023 |
Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial.
Topics: Analgesics, Opioid; Chlorpromazine; Dopamine Antagonists; Dose-Response Relationship, Drug; Double-B | 2020 |
Neurodevelopmental Outcomes of Neonates Randomized to Morphine or Methadone for Treatment of Neonatal Abstinence Syndrome.
Topics: Female; Humans; Infant; Infant, Newborn; Male; Methadone; Morphine; Narcotics; Neonatal Abstinence S | 2020 |
Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome.
Topics: Administration, Oral; Administration, Sublingual; Analgesics, Opioid; Buprenorphine; Double-Blind Me | 2017 |
Treatment of neonatal abstinence syndrome in preterm and term infants.
Topics: Adult; Analgesics, Opioid; Chloral Hydrate; Dose-Response Relationship, Drug; Drug Administration Sc | 2013 |
Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Analysis of Variance; Clonidine; Drug Ther | 2013 |
Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial.
Topics: Administration, Oral; Analgesics, Opioid; Chemotherapy, Adjuvant; Drug Administration Schedule; Huma | 2015 |
Laser Acupuncture for Neonatal Abstinence Syndrome: A Randomized Controlled Trial.
Topics: Acupuncture Therapy; Combined Modality Therapy; Female; Humans; Infant, Newborn; Lasers; Male; Morph | 2015 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Topics: Administration, Sublingual; Adult; Birth Weight; Buprenorphine; Cytomegalovirus Infections; Dose-Res | 2011 |
A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome.
Topics: Double-Blind Method; Humans; Infant, Newborn; Morphine; Narcotics; Neonatal Abstinence Syndrome; Opi | 2004 |
Neurobehavioral effects of treatment for opiate withdrawal.
Topics: Analgesics, Opioid; Drug Therapy, Combination; Heroin; Humans; Hypnotics and Sedatives; Infant Behav | 2005 |
Management of neonatal abstinence syndrome in neonates born to opioid maintained women.
Topics: Adult; Apgar Score; Female; Gestational Age; Humans; Infant, Newborn; Male; Methadone; Morphine; Neo | 2007 |
Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants.
Topics: Analgesics, Opioid; Drug Therapy, Combination; Heroin; Hospital Costs; Humans; Hypnotics and Sedativ | 2002 |
33 other studies available for phenobarbital and Abstinence Syndrome, Neonatal
| Article | Year |
|---|---|
Do small for gestational age infants have less severe neonatal abstinence syndrome?
Topics: Female; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Neonatal Abstinence Syn | 2022 |
[Neonatal abstinence syndrome due to kratom].
Topics: Analgesics, Opioid; Female; Humans; Infant, Newborn; Mitragyna; Neonatal Abstinence Syndrome; Opioid | 2023 |
Neonatal abstinence syndrome management in California birth hospitals: results of a statewide survey.
Topics: Analgesics, Opioid; Breast Feeding; California; Clonidine; Health Care Surveys; Humans; Infant Care; | 2020 |
Stereoselective Analysis of Methadone and EDDP in Laboring Women and Neonates in Plasma and Dried Blood Spots and Association with Neonatal Abstinence Syndrome.
Topics: Analgesics, Opioid; Anticonvulsants; Dried Blood Spot Testing; Female; Humans; Infant, Newborn; Labo | 2021 |
Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome.
Topics: Analgesics, Opioid; Clonidine; Humans; Infant, Newborn; Length of Stay; Methadone; Morphine; Neonata | 2020 |
Is Maternal Methadone Dose Associated with the Severity of Neonatal Abstinence Syndrome?
Topics: Female; Humans; Infant, Newborn; Methadone; Morphine; Neonatal Abstinence Syndrome; Opioid-Related D | 2022 |
Phenobarbital and Clonidine as Secondary Medications for Neonatal Opioid Withdrawal Syndrome.
Topics: Analgesics; Analgesics, Opioid; Clonidine; Drug Administration Schedule; Drug Therapy, Combination; | 2021 |
Neonatal abstinence syndrome due to prenatally citalopram exposure: A case report.
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; F | 2017 |
Outpatient Pharmacotherapy for Neonatal Abstinence Syndrome.
Topics: Ambulatory Care; Analgesics, Opioid; Drug Therapy, Combination; Emergency Service, Hospital; Facilit | 2018 |
[Neonatal abstinence syndrome after maternal use of tramadol].
Topics: Adult; Analgesics, Opioid; Female; Humans; Infant, Newborn; Neonatal Abstinence Syndrome; Opioid-Rel | 2013 |
Home-based detoxification for neonatal abstinence syndrome reduces length of hospital admission without prolonging treatment.
Topics: Adult; Analgesics, Opioid; Breast Feeding; Cost Control; Female; Home Care Services, Hospital-Based; | 2014 |
Variation in treatment of neonatal abstinence syndrome in US children's hospitals, 2004-2011.
Topics: Comorbidity; Female; Hospital Charges; Hospitals, Pediatric; Humans; Infant, Newborn; Length of Stay | 2014 |
Adjunctive therapy for neonatal opioid dependence: do we really know what's best?
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Clonidine; Female; Humans; Male; Morphine; | 2014 |
Adjunctive therapy for neonatal abstinence syndrome: why not personalize it for each infant based on their in-utero exposure?
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Clonidine; Female; Humans; Male; Morphine; | 2014 |
A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome.
Topics: Adult; Clinical Protocols; Female; Humans; Hypnotics and Sedatives; Infant, Newborn; Infant, Prematu | 2014 |
Prematurity reduces the severity and need for treatment of neonatal abstinence syndrome.
Topics: Adult; Anticonvulsants; Australian Capital Territory; Female; Gestational Age; Humans; Infant, Newbo | 2015 |
Design of pediatric oral formulations with a low proportion of methadone or phenobarbital for the treatment of neonatal abstinence syndrome.
Topics: Administration, Oral; Chemistry, Pharmaceutical; Drug Design; Drug Packaging; Drug Stability; Humans | 2016 |
Rooming-In to Treat Neonatal Abstinence Syndrome: Improved Family-Centered Care at Lower Cost.
Topics: Analgesics, Opioid; Drug Utilization; Hospital Costs; Humans; Hypnotics and Sedatives; Infant, Newbo | 2016 |
Neonatal Abstinence Syndrome: Twelve Years of Experience at a Regional Referral Center.
Topics: Buprenorphine; Diseases in Twins; Female; Hospitalization; Humans; Infant, Newborn; Male; Methadone; | 2017 |
High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome.
Topics: Adult; Anticonvulsants; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Infant, Ne | 2009 |
Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate.
Topics: Blood Pressure; Chloral Hydrate; Clonidine; Drug Therapy, Combination; Female; Humans; Hypnotics and | 2010 |
Neonatal abstinence syndrome (NAS) after intrauterine exposure to tramadol.
Topics: Analgesics, Opioid; Breast Feeding; Female; Humans; Hypnotics and Sedatives; Infant, Newborn; Matern | 2010 |
Infants born to mothers under phenobarbital treatment: correlation between serum levels and clinical features of neonates.
Topics: Adult; Anticonvulsants; Cohort Studies; Epilepsy; Female; Hospitals, University; Humans; Infant, New | 2011 |
Profile of infants born to drug-using mothers: a state-wide audit.
Topics: Australian Capital Territory; Breast Feeding; Congenital Abnormalities; Female; Hospitalization; Hos | 2013 |
Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey.
Topics: Humans; Hypnotics and Sedatives; Infant, Newborn; Injections, Intravenous; Intensive Care Units, Neo | 2006 |
[A multidisciplinary approach is necessary in the neonatal withdrawal syndrome].
Topics: Adult; Female; Humans; Hypnotics and Sedatives; Infant, Newborn; Male; Methadone; Narcotics; Neonata | 2006 |
Neonatal narcotic withdrawal in Hong Kong Chinese.
Topics: Asian People; Case-Control Studies; Chlorpromazine; Female; Hong Kong; Humans; Infant, Newborn; Narc | 1994 |
Neonatal withdrawal from maternal volatile substance abuse.
Topics: Acidosis; Cohort Studies; Female; GABA Modulators; Humans; Infant, Newborn; Male; Neonatal Abstinenc | 1996 |
A survey of the management of neonatal opiate withdrawal in England and Wales.
Topics: Chlorpromazine; England; Female; Hospitals, Maternity; Humans; Infant, Newborn; Male; Narcotics; Neo | 1996 |
[Newborn infant of drug-addicted mother: maternal, perinatal, neonatal aspects, and neonatal abstinence syndrome].
Topics: Adult; Chlorpromazine; Female; Humans; Infant, Low Birth Weight; Infant, Newborn; Neonatal Abstinenc | 1991 |
Appraisal and caregiving for the drug addicted infant.
Topics: Humans; Infant, Newborn; Narcotics; Neonatal Abstinence Syndrome; Nursing Assessment; Patient Care P | 1989 |
The influence of pharmacotherapy on the neonatal sleep patterns of infants born to opiate-addicted mothers.
Topics: Drug Therapy, Combination; Female; Humans; Infant, Newborn; Male; Methadone; Narcotics; Neonatal Abs | 1987 |
Infants of drug-addicted mothers.
Topics: Acquired Immunodeficiency Syndrome; Female; Humans; Infant; Infant, Newborn; Neonatal Abstinence Syn | 1988 |